Results 141 to 150 of about 6,491 (191)
Improving the prescribing of palivizumab
Journal of Paediatrics and Child Health, 2018 AimPalivizumab prevents respiratory syncytial virus (RSV) in children at high risk of severe disease. This paper reviews the use and effectiveness of palivizumab at two tertiary paediatric hospitals (hospitals A and B) in New South Wales, Australia.MethodsChildren prescribed palivizumab during the pre‐intervention period, 1 January 2013 until 31 ...
Simone Trist +4 more
openaire +3 more sources
Cost‐effectiveness of palivizumab in New Zealand
Journal of Paediatrics and Child Health, 2002 Objective: To establish the preterm infant hospitalization risks from respiratory syncytial virus (RSV) in New Zealand and the net cost per hospitalization averted by palivizumab.Methods: The 437 infants born < 32 weeks gestation in 1997 and treated at five major neonatal units were identified.
Vogel, AM +9 more
openaire +6 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Drugs, 1999
The humanised monoclonal antibody palivizumab has been developed for prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants at high risk; RSV is the most common cause of lower respiratory tract infections in infants.
L J, Scott, H M, Lamb
+5 more sources
The humanised monoclonal antibody palivizumab has been developed for prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants at high risk; RSV is the most common cause of lower respiratory tract infections in infants.
L J, Scott, H M, Lamb
+5 more sources
Pediatric Pulmonology, 2016 Respiratory syncytial virus infection represents a clinical burden among young children under 24 months. Palivizumab is the only drug licensed in Italy for the prevention of serious lower respiratory tract disease requiring hospitalization caused by ...
Ersilia Lucenteforte, Salvatore De Masi
exaly +3 more sources
Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab
Journal of Paediatrics and Child Health, 2006 Background: a monoclonal antibody, palivizumab, directed against respiratory syncytial virus (RSV) has been shown to decrease hospitalisation rates. Because of its expense, the cost-effectiveness of this agent should be determined for high-risk groups.
Robert Norton, Petra G Buettner
exaly +2 more sources
Reactions Weekly, 2018
Infektiologie Update 2018; 26. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie (PEG)
+5 more sources
Infektiologie Update 2018; 26. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie (PEG)
+5 more sources
Hospital Medicine, 1999
Respiratory syncytial virus (RSV) affects almost all children in their first 2 years of life and can cause severe or even life-threatening disease in some at-risk infants. Treatment is limited and there is currently no safe or effective vaccine. However, a new monoclonal antibody, palivizumab, reduces RSV hospitalization by 55% in at-risk groups if ...
openaire +2 more sources
Respiratory syncytial virus (RSV) affects almost all children in their first 2 years of life and can cause severe or even life-threatening disease in some at-risk infants. Treatment is limited and there is currently no safe or effective vaccine. However, a new monoclonal antibody, palivizumab, reduces RSV hospitalization by 55% in at-risk groups if ...
openaire +2 more sources
Comments on Palivizumab (Synagis)
Pediatrics, 1999Caregivers and third-party payors need additional information from the Impact study1investigators to determine the appropriate use of palivizumab (Synagis) in select premature infants with increased risk of respiratory syncytial virus (RSV)-associated hospitalization.
F W, Moler +3 more
openaire +2 more sources
Administration of Palivizumab in the NICU
Hospital Pediatrics, 2016BACKGROUND: The American Academy of Pediatrics recommends palivizumab prophylaxis against respiratory syncytial virus (RSV) for infants at high risk for severe disease within 72 hours of hospital discharge to prevent community-associated RSV.
Neika, Vendetti +5 more
openaire +2 more sources
Pediatric Infectious Disease Journal, 2015
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in infants. Palivizumab, a means of passive prophylaxis, relies on patient adherence to ensure therapeutic effectiveness. The objective of this study is to evaluate the association between adherence and the incidence of RSV-associated outcomes and to identify ...
Parco, Chan +5 more
openaire +2 more sources
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in infants. Palivizumab, a means of passive prophylaxis, relies on patient adherence to ensure therapeutic effectiveness. The objective of this study is to evaluate the association between adherence and the incidence of RSV-associated outcomes and to identify ...
Parco, Chan +5 more
openaire +2 more sources